Hare 2002.

Study characteristics
Methods	Single‐centre (Michigan, USA) pilot 'open‐label' comparative trial with 'alternate assignment' 14 participants with CF and an acute exacerbation were admitted to hospital for IV course of antibiotics (duration of admission not reported) and were alternately assigned to receive Percussivetech HF device or standard manual CCPT 4 times daily during hospitalisation.
Participants	14 participants Age range 8–28 years 10 male, 4 female
Interventions	PercussiveTech HF: 4 times per day during hospitalisation CCPT: standard manual CCPT, 4 times per day during hospitalisation
Outcomes	"Complete" PFTs (FVC, FEV1, FEF25–75 and RV) and clinical scores measured at baseline and at discharge. Participants were monitored for complications (haemoptysis, hypoxaemia, pneumothorax).
Notes	Study reported in 1 abstract from 16th NACF conference (Hare 2002). Jadad score: 0/5.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Non‐random "alternate assignment," and final numbers in each group not reported, or how the first participant was allocated.
Allocation concealment (selection bias)	High risk	Allocation not concealed as "alternate assignment" to groups.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No blinding: not feasible (participants), open‐label (personnel).
Blinding of outcome assessment (detection bias) All outcomes	High risk	Non‐blinded: open‐label study.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information regarding withdrawals or dropouts in abstract.
Selective reporting (reporting bias)	High risk	No data or statistical analysis provided. Outcomes were discussed in narrative form only.
Other bias	High risk	No data included in abstract, results presented descriptively. Numbers allocated to each group not reported, magnitude of change in clinical outcomes not reported. Nature of statistical analysis not reported. Length of admission not reported, with risk that this differed between groups. Study supported by Vortran Medical Tech (Percussivetech HF manufacturer).